A Phase II, Single-center, Single-arm Study Evaluating the Safety and Efficacy of Golidocitinib in the Management of Newly Diagnosed Peripheral T Cell Lymphoma Patients (GOLDEN Study) and Correlative Study
Clinical trial NCT06630091 · RECRUITING
Trial details
- NCT number
- NCT06630091
- Sponsor
- M.D. Anderson Cancer Center
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-02-21
- Primary completion
- 2027-07-05
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.